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Introduction
Toxic liver injury includes a wide range of diseases 
associated with hepatotoxic effects of substances of various 
origins, which cause morphological changes in liver tissue 
and associated metabolic disorders. Hepatotoxic effects 
are inherent in some domestic and industrial chemicals, 
pesticides, alcohol, a number of medications, nutritional 
supplements, herbal products, and the like. Toxic hepatitis 
is an inflammatory disease of liver caused by above agents. 
It may develop within hours or days after exposure to 
toxicant. In other cases, the development of symptoms 
may last for months of regular exposure. The incidence of 
toxic hepatitis is 10-15 per 10 000 in general population.1 
Drug-induced liver injury (DILI) contributes the most 
to this category of diseases because of leading role of 
the liver in drug metabolism and biotransformation. 
The ability to cause liver damage is implicated in more 
than 900 medications and is the most common reason 
for drug withdrawal from the pharmaceutical market.2 
DILI accounts for approximately 10% of all cases of acute 
hepatitis and approximately 2% of chronic liver disease and 
cirrhosis. It is responsible for over 50% of all cases of acute 
liver failure (ALF).2-4 Symptoms of drug-induced damage 
encompass almost all known liver lesions - both acute and 
chronic. Acute lesions may be cytotoxic (hepatocellular) 
or cholestatic. Chronic ones include hepatocellular, 
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Abstract
Introduction: Oxidative stress has been 
suggested as the main trigger and pathological 
mechanism of toxic liver injury. Effects of 
powerful free radical scavenger С60 fullerene 
on rat liver injury and liver cells (HepG2 line) 
were aimed to be discovered.
Methods: Acute liver injury (ALI) was 
simulated by single acetaminophen (APAP, 
1000 mg/kg) administration, on a chronic 
CLI, by 4 weekly APAP administrations. 
Pristine C60 fullerene aqueous colloid solution 
(C60FAS; initial concentration 0.15 mg/mL) was administered per os or intraperitoneally at a dose 
of 0.5 mg/kg (ALI) or 0.25 mg/kg (CLI) daily for 2 or 28 days, respectively, after first APAP dose. 
Animals were sacrificed at 24th hour after the last dose. Biochemical markers of blood serum 
and liver autopsies were analyzed. EGFR expression in HepG2 cells after 48-hour incubation with 
C60FAS was assessed. 
Results: Increase of serum conjugated and unconjugated bilirubin (up to 1.4-3.7 times), ALT (by 
31-37%), and AST (by 18%) in non-treated ALI and CLI rats were observed, suggesting the hepatitis 
(confirmed by histological analysis). Liver morphological state (ALI, CLI), ALT (ALI and CLI), 
bilirubin (CLI), α-amylase, and creatinine (ALI) were normalized with C60FAS administration in 
both ways, which may indicate its protective impact on liver. However, unconjugated bilirubin 
sharply increased in ALI animals receiving C60FAS (up to 12 times compared to control), suggesting 
the augmentation of bilirubin metabolism. Furthermore, C60FAS inhibited EGFR expression in 
HepG2 cells in a dose-dependent manner.
Conclusion: C60FAS could partially correct acute and chronic toxic liver injury, however, it could 
not normalize bilirubin metabolism after acute exposure. 
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is hydrophobic molecule and is able to be embedded 
into biological membranes and thus to penetrate into the 
cell.22 Therefore, C60 is discovered as a promising drug 
carrier due to its ability to be functionalized with different 
molecules and therapeutics on the one hand, and to 
penetrate the cell membrane on the other hand.23,24 It also 
possesses antiviral activity because of steric compatibility 
with hydrophobic cavity of viral enzymes.25,26 C60 also can 
be used as potential photosensitizer in photodynamic 
therapy due to its ability to generate reactive oxygen species 
(ROS) after photoirradiation.20,27 It should be noted that 
double bonds in the C60 framework are electron deficient, 
which determines the electron-acceptor properties of the 
molecule and its ability to easily attach reagents containing 
unpaired electrons (i.e. free radicals).28 Due to this ability, 
C60 could act in biological systems as scavenger of free 
radicals, in particular hydroxyl and superoxide anions, 
which results in its anti-tumor, anti-inflammatory and 
hepatoprotective properties.22,29-34 In an aqueous solution, 
pristine C60 forms nanosize clusters.
35,36 Additionally, 
water-soluble pristine C60 is non-toxic in in vitro and in 
vivo systems at least at low concentrations37,38 and can be 
accumulated in liver.39 Therefore, it is suggested to be a 
potential treatment of this organ.
In our previous studies we demonstrated that C60 
realized anti-inflammatory and hepatoprotective effects 
on a model of acute colonic inflammation.32 We also 
showed the ability of C60 to improve liver biochemical 
parameters and histological state, particularly to diminish 
liver inflammation and fibrotic degeneration, under 
α-naphthylisothiocyanate-induced acute cholangitis.40 In 
addition, Halenova et al30 revealed that C60 could prevent 
CCl4-induced acute liver injury (ALI). However, they 
used the dose of C60 exceeded than that in the current 
experiment in 3 times. Some studies demonstrated the 
genotoxic and prooxidative effect of C60 realized in a dose-
dependent manner,41,42 whereas another ones – at least 
no prooxidative and rather antioxidant effects.43 Thus, 
the possible effect of lower dose of C60 deserves to be 
investigated. Furthermore, all mentioned works described 
the impact of C60 under acute liver pathology. As the 
processes and mechanisms of development of chronic 
liver injury and liver adaptation differ from those of acute 
disease,44 the chronic action of the substance might differ 
from acute one. Moreover, if any substance was applied for 
a prolonged period, possible cumulative effect also should 
be taken into consideration. 
Thus, the purpose of this work was to study the effect 
of water-soluble biocompatible pristine С60 on the rat liver 
function under its acute and chronic toxic injury and on 
liver cells in vitro as well as to evaluate the ability of these 
nanoparticles to prevent extrahepatic complications.
Materials and Methods
Chemical reagents
Acetaminophen (Merck, Darmstadt, Germany) was 
cholestatic, vascular, or neoplastic manifestations. 
The production of free radicals such as reactive oxygen 
and nitrogen species has been considered as an early event 
of drug hepatotoxicity and an indicator of hepatotoxic 
potential. A lot of drugs can cause oxidative stress in the 
liver, in particular the increase in the number of cellular 
prooxidants, lipid peroxidation, and the depletion of a pool 
of antioxidants. The oxidative stress induces irretrievable 
alteration of lipids, proteins, and DNA and therefore 
triggers hepatic damage. Moreover, it also modulates the 
signal pathways controlling normal biological functions. 
Since these pathways regulate genes transcription, 
protein expression, cell apoptosis, and hepatic stellate cell 
activation, oxidative stress is considered to be one of the 
pathological mechanisms leading to the initiation and 
progression of various liver diseases (chronic hepatitis, 
alcoholic liver disease, and non-alcoholic steatohepatitis 
(NASH) etc.). Moreover, systemic oxidative stress arising 
during liver disease can also cause damage of extra-hepatic 
organs, such as pancreatic and renal failure and even brain 
impairment.1,5,6
A lot of studies demonstrate that agents having 
antioxidant activity also exhibit hepatoprotective 
properties.6,7 Some natural and nutritional antioxidants 
such as vitamins C and E, zinc, selenium, coenzyme 
Q10, methionine, alpha lipoic acid, N-acetylcysteine, and 
silymarin are undergoing the clinical trials in phases II/
III and even IV.8-14 Some of them have been approved for 
treating patients with fatty liver disease and NASH in 
some countries.15,16 Thus, antioxidant therapy could be 
an effective approach for the prevention and treatment of 
liver disease.
An important area of research in modern medicine 
concerns nanomaterials as promising agents with a 
wide range of mediсal applications. Nanomaterials are 
currently used as carriers to deliver drugs and other 
substances to specific types of cells.17 Nanoparticles as part 
of chips with immobilized bioactive molecules are used 
in diagnostic techniques.18 Carbon, metal and synthetic 
nanomaterials are utilized in tissue engineering including 
organ transplantation and tissue regeneration.19 Carbon-
based nanomaterials attract the attention as the most 
“biocompatible” ones. Among them fullerenes take one of 
the leading places.20 
C60 fullerene (C60) is almost a spherical molecule whose 
surface consists of 60 carbon atoms. The C60 spherical 
surface contains 20 hexagonal and 12 pentagonal 
structures. Bonds between adjacent hexagons are 
double, and those between hexagons and pentagons are 
single. Thus, hexa- and pentagon units are connected 
by a conjugated π-electron system.21 The diameter of 
the C60 molecule is 0.72 nm, which is close to that of 
polypeptides’ α-helix and the steroid molecules. Thus, 
the steric compatibility of C60 with biological structures 
such as receptor recognizing sites or enzyme active 
centers may be suggested. Non-modified (pristine) C60 
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used for the simulation of liver injury. Reagent kits for 
detection of alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), total and direct (conjugated) 
bilirubin, creatinine, urea (Filisit diagnosis, Dnipro, 
Ukraine), alkaline phosphatase (ALP), α-amylase, 
triglycerides and total protein (Diagnosticum Zrt, 
Budapest, Hungary) were used in biochemical assays. 
Ethanol, acetic acid (Henan Bright Commercial Co., 
Zhengzhou, China), picric acid, formalin (Biopharma, 
Kyiv, Ukraine), paraffin, hematoxylin, eosin, orange G 
(Merck, Darmstadt, Germany) were used in histological 
assays. Dulbecco’s Modified Eagle Medium (DMEM), fetal 
bovine serum (FBS), L-glutamine (Merck, Darmstadt, 
Germany), and gentamicin (Biopharma, Kyiv, Ukraine) 
were used for cell culturing. Epidermal growth factor 
receptor (EGFR) monoclonal antibodies and reagent kit 
for immunohistochemical visualization (Dako, Santa 
Clara, CA, USA) were used in immunohistochemical 
assay. Au(111) films (SPI Supplies, West Chester, PA, USA) 
were used for scanning tunneling microscopy (STM). We 
used following equipment: light microscope Olympus 
BX-41 (Olympus Europa GmbH, Munich, Germany), 
spectrophotometer ULAB 101 (Ulab, Kyiv Ukraine), CO2 
incubator (Memmert GmbH, Schwabach, Germany), 
STM (NT-MDT Spectrum instruments, Moscow, Russia), 
and Zetasizer Nano-ZS90 (Malvern, Worcestershire, UK).
Preparation and characterization of C60 fullerene 
aqueous colloid solution 
A highly stable C60 fullerene aqueous colloid solution 
(C60FAS) was prepared according to the protocols 
described before.36 The initial concentration of C60 was 
0.15 mg/mL. 
Dynamic light scattering (DLS) and zeta potential 
measurements (ζ) were used for ascertaining the 
hydrodynamic size and electrokinetic potential of C60 
particles in a prepared C60FAS. Measurements were 
conducted on Zetasizer Nano-ZS90 at 25°C. Obtained 
results were evaluated using the Smoluchowski 
approximation, which is known to be rigorously valid only 
for spherical-like particles.
Samples for STM analysis were obtained after 
deposition of C60 on an Au(111) surface by precipitation 
from the droplet of corresponding stock solutions. STM 
measurements were performed after complete evaporation 
of the solvents. The morphology of C60 particles in 
deposited films was monitored using STM technique. 
Typical values of the tunneling current and voltage were 
chosen within the ranges of 0.01–0.1 nA and 0.1–0.8 V, 
respectively. 
Animals
Studies were conducted using 64 Wistar male rats with 
the initial body weight of 200±10 g (acute trial) and 
130±10 g (chronic one), which were kept in vivarium of 
Taras Shevchenko National University of Kyiv at natural 
light on a standard diet with free access to drinking water. 
All experiments were conducted in compliance with 
bioethic principles, legislative norms, and provisions of 
the European Convention for the Protection of Vertebrate 
Animals used for Experimental and Other Scientific 
Purposes (Strasbourg, 1986), General Ethical Principles 
for Experiments on Animals, adopted by the First 
National Bioethics Congress (Kyiv, 2001), and approved 
by an institutional review committee.
Design of the studies
ALI was simulated by a single oral administration of 
APAP at a dose of 1000 mg/kg45 dissolved in sunflower 
oil (total volume 0.5 mL). In 5 and 24 hours after APAP 
dose, animals were administered with C60FAS in a volume 
corresponding to the amount of С60 0.5 mg/kg body 
weight (total received dose equal to 1 mg/kg) either 
intraperitoneally (i.p.) or per os (p.o.) (Table 1). 
To induce chronic liver injury (CLI), animals were 
ingested with APAP weekly for 28 days at a dose 
corresponding to that in acute study. In 24 hours, animals 
were administered with C60FAS in a volume corresponding 
to the amount of С60 0.25 mg/kg body weight daily during 
28 days (total received dose equal to 5 mg/kg) (Table 1). 
All manipulations with animals in comparison groups 
were conducted similarly to animals of experimental ones, 
including the administration of solvents. 
As acute and chronic effects of C60FAS on healthy 
animals were previously investigated and described,32,39 
we did not include the description of these groups in the 
manuscript. In 24 hours after the last dose, animals were 
euthanized by inhalation of CO2 and subsequent cervical 
dislocation.
Biochemical assays
The blood for biochemical analysis was collected 
immediately after the sacrifice from the femoral vein, left 
for 20 minutes to form a clot and then centrifuged for 10 
minutes at 1000 g. ALT, AST, ALP and α-amylase enzymes, 
total and direct (conjugated) bilirubin, triglycerides, 
creatinine, urea and total protein as markers of liver, 
kidneys and pancreas functional states were determined 
in blood serum according to the protocols provided by the 
manufacturers. 
Histological assay
The liver fragments were harvested immediately after 
the sacrifice and fixed in Bouin’s mixture for 14 days for 
histological assay. Then, they were embedded into paraffin, 
sliced into 5 𝜇m sections, stained with hematoxylin-eosin-
orange, and examined under the light microscope. States 
of liver centrilobular and periportal areas were estimated 
separately. 
In vitro immunohistochemical assay 
HepG2 cells were cultured under standard conditions 
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(37°C, 5% CO2, 95% humidity), in DMEM containing 
10% FBS, 2 mM L-glutamine, and 40 mg/mL gentamicin. 
To evaluate the EGFR expression, the cells were seeded on 
coated glass in 6-well plates with 2×104 cells/cm2 densitу 
and used in 48 hours of cultivation. Cells were incubated 
in medium containing 10 or 100 μg of C60FAS per mL for 
48 hours. Immunohistochemical assay was performed 
using primary EGFR monoclonal antibodies according to 
the protocol provided by the manufacturer. In addition, 
specimens were stained with hematoxylin for nuclei 
visualization. The number of immunopositive cells was 
counted in 10 random microscopic fields of view for each 
sample using a standard scale of measurement (object-
micrometer) at the same magnification and calculated as 
a percentage of the total cell number taken for 100%. At 
least 200 cells were counted.
Statistical analysis
The Gaussian distribution of the data was estimated using 
Shapiro-Wilk test. As the distribution was normal, the 
statistical analysis of data was performed using one-way 
analysis of variance (ANOVA) with the Tukey post hoc 
test. The difference was considered statistically significant 
at P<0.05. 
Results
DLS and STM studies 
To fully understand the bioactivity of prepared water-
soluble C60 particles, we examined their size distribution 
profile and electrokinetic potential (ζ potential) value with 
DLS technique. In C60FAS, C60 have the hydrodynamic 
diameter of 65 nm. Tested C60 nanoparticles demonstrated 
a slightly negative average surface charge (ζ= -13.70 mV), 
indicating a further tendency for their aggregation. Finally, 
a studied nanoparticle system with polydispersity index 
value 0.25 was indicated that has moderately disperse 
distribution. 
STM image of particles deposited on Au(111) surface 
from C60FAS is presented in Fig. 1. The height of particles 
was estimated along the cross-section line (Z-profile) 
marked by yellow (Fig. 1 top). As one can see, C60FAS in 
addition to single C60 molecules (~0.72 nm) also contains 
nanoparticles (C60 aggregates) with a height more than 1.2 
nm (Fig. 1 bottom). 
Acute liver injury
The liver of ALI animals demonstrated no visible lesions. 
However, the blood vessels overflow and sinusoid 
hemocapillars elevation was observed at light microscopy 
level. Signs of hepatocyte necrosis, protein and lipid 
dystrophy were also detected, as well as the ground-glass 
hepatocytes occurrence, lymphocytic infiltration and 
fibrosis of portal tracts (Fig. 2, Table 2). Observed features 
have been suggested to be typical for the acute hepatitis.46
Under acute APAP exposure, ALT, AST, and 
unconjugated (indirect) bilirubin increased ,by 37%, 
18% and 185%, respectively, as well as conjugated 
(direct) bilirubin and ALP which increased by 34% and 
Table 1. Experimental groups
Experimental groups
Study, duration
Acute, 48 h Chronic, 28 days
APAP C60FAS, corresponded to dose of C60
APAP C60FAS, corresponded to dose of C60
Control, n=8 - - - -
APAP, n=8 1000 mg/kg once - 1000 mg/kg 4 times weekly -
APAP+C60FAS i.p., n=8 1000 mg/kg once
0.5 mg/kg 2 times (in 5 and 
24 h after APAP) i.p. 1000 mg/kg 4 times weekly 0.25 mg/kg daily during 28 days i.p.
APAP+C60FAS p.o., n=8 1000 mg/kg once
0.5 mg/kg 2 times (in 5 and 
24 h after APAP) p.o. 1000 mg/kg 4 times weekly 0.25 mg/kg daily during 28 days p.o.
Note. APAP: acetaminophen, C60FAS: C60 fullerene aqueous colloid solution, i.p.: intraperitoneally, p.o.: per os.
Fig. 1. STM image of C60 submonolayer film deposited from C60FAS (0.15 
mg/mL) on Au(111) surface. Scanning parameters: It=93 pA, Ut=713 mV 
(top); Z-profile (bottom) along the yellow line marked on the image (top).
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14% respectively (P>0.1), suggesting the damage of 
hepatocytes. The level of creatinine also tended up by 
15% (P>0.1), which might indicate renal dysfunction. 
Additionally, triglycerides level was diminished by 48%, 
maybe due to the impairment of their absorption from the 
gastrointestinal tract and/or a violation of their synthesis 
in liver and, consequently, insufficient entering into the 
blood. The level of total protein was unchanged. The 
serum α-amylase was significantly lower (23%) compared 
to control, which is a typical phenomenon of acute and 
chronic hepatitis (Fig. 3).46
Blood vessels and hemocapillars dilation, signs of 
hemostasis, and thrombosis were observed in ALI rats 
receiving C60FAS by both ways. However, hepatocytes 
protein dystrophy was weaker compared to APAP group 
and lipid dystrophy was not detected. Moreover, less 
number of necrotic cells was found. In addition, areas of 
fibrosis and lymphocytic infiltration surrounding portal 
tracts were diminished under C60FAS i.p. (Fig. 2, Table 2). 
In C60FAS-received ALI rats, either i.p. and p.o. ALT 
rates closed to control values, indicating reduction 
of hepatocyte cytolysis. At the same time, AST rates 
remained elevated (by 21% compared to control), the 
unconjugated bilirubin even more increased (up to 
12 and 8 times compared to control and up to 4 and 3 
times compared to APAP group for C60FAS i.p. and p.o., 
respectively), which might indicate a bilirubin metabolism 
disorder. An increase of unconjugated bilirubin fraction 
without significant changes in conjugated one may be the 
consequence of increased bilirubin production (due to 
hemolysis) or a violation of its hepatic absorption and/or 
conjugation. C60 has been shown to have weak hemolytic 
properties,47,48 which might be the reason of observed 
changes. On the other hand, it has been established that 
the increase of unconjugated bilirubin may also occur 
due to liver function disorders.49 Hyperbilirubinemia may 
follow as increased bilirubin production, as abnormalities 
of any stage of its metabolism, including capture 
from the blood, intracellular conjugation and biliary 
excretion. Unconjugated bilirubin elevation is often 
caused by drugs affecting any stage of its metabolism. 
Usually, the effect of those on the uridine 5'-diphospho-
glucuronosyltransferase (UDP-glucuronosyltransferase) 
catalyzing the conversion of unconjugated bilirubin into 
conjugated one by conjugation with glucuronic acid50 is 
taken into account. Although, according to Shipelin et 
al,51 C60 does not affect the activity of this enzyme, it can 
affect another bilirubin metabolic pathways, in particular, 
its transport within the hepatocyte via glutathione-S-
transferase. Recently, we have shown that C60 could inhibit 
its activity.32
C60FAS when administered by both ways also caused 
reduction of serum triglycerides and normalized 
α-amylase and creatinine, indicating the pancreatic and 
renal function restore (Fig. 3). Serum triglycerides decrease 
might be an indirect consequence of C60 antioxidant 
properties; Halim et al.52 showed that the therapeutic use 
of antioxidants leads to triglycerides accumulation in the 
Fig. 2. Microphotographs of the liver for ALI rats received C60FAS: 1 – control; 2 – APAP; 3 – APAP+C60FAS i.p.; 4 – APAP+C60FAS p.o.; A and B - centrilobular 
and periportal areas, respectively. Hematoxylin-eosin-orange staining, ×400, scale 100 µm. Sinusoids and blood vessels dilation (2 A, 3 A, 4 A), lymphocytic 
infiltration of portal tracts (2 B, 4 B) and surrounding tissue (2 B), hepatocyte necrosis (2 A).
Table 2. Pathological changes of liver of ALI rats receiving C60FAS
Pathological changes
Experimental groups
Control APAP APAP+C60FAS i.p. APAP+C60FAS p.o.
Protein dystrophy of hepatocytes - ++ + +
Lipid dystrophy of hepatocytes - ++ + -
Ground-glass hepatocytes - ++ + +
Necrotic hepatocytes - +++ + +
Connective tissue accumulation - ++ + ++
Lymphocytes accumulation + +++ ++ +++
Blood vessel dilation - ++ ++ ++
Note. APAP: acetaminophen, C60FAS: C60 fullerene aqueous colloid solution, i.p.: intraperitoneally, p.o.: per os.; trait intensity: “-“ – not observed, “+”: 
single or slight, “++”: moderate, “+++”: strong.
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liver and, consequently, to decline their levels in blood 
serum.
Chronic liver injury
The liver of CLI rats was spotty, had dilated large blood 
vessels, suggesting the macroscopic features of hepatitis. 
Pathological changes were aggravated compared to acute 
ones; blood vessels and sinusoid hemocapillars dilation, 
thrombosis and hemostasis, hepatocytes protein and 
lipid dystrophy, necrotic and apoptotic cells, a lot of 
ground-glass hepatocytes, portal tracts’ fibrosis and 
lymphocytic infiltration were observed (Fig. 4, Table 3). 
Fig. 3 Serum biochemical markers of liver, pancreas and kidney functional states for ALI rats received C60FAS normalized against control: 
1 – control; 2 – APAP; 3 – APAP+C60FAS i.p.; 4 – APAP+C60FAS p.o.; *P<0.05 compared to control, #P<0.05 compared to APAP.
Fig. 4. Microphotographs of the liver for CLI rats received C60FAS: 1 – control; 2 – APAP; 3 – APAP+C60FAS i.p.; 4 – APAP+C60FAS p.o.; 
A and B - centrilobular and periportal areas, respectively. Hematoxylin-eosin-orange staining, ×400, scale 100 µm. Sinusoids and blood 
vessels dilatation and overflow (2 A, 4 A), lymphocytic infiltration of portal tracts and surrounding tissue (2 B), hepatocyte necrosis (2 A)
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ALT activity increased (by 31%), as well as conjugated 
and unconjugated bilirubin (up to 2 and 3.7 times, 
respectively), indicating chronic hepatitis development.46 
Creatinine and α-amylase tended up (by 23% and 25%, 
respectively, P>0.1), suggesting the kidney and pancreas 
function impairment. At the same time, urea decreased by 
22% (Fig. 5), while other parameters were unchanged.
C60FAS if applied i.p. improved the liver state; the blood 
vessels and sinusoid hemocapillars were dilated slightly, 
less overflowed and with no thrombosis compared to 
non-treated CLI animals. Necrotic and apoptotic foci 
were local, fibrosis and lymphocytic infiltration of 
portal tracts decreased significantly. However, signs of 
hepatocytes dystrophy still occurred (Fig. 4, Table 3). ALT, 
unconjugated bilirubin, and urea restored to control values, 
but conjugated bilirubin remained elevated. Moreover, 
creatinine and α-amylase increased significantly (by 37% 
and 34%, respectively), which might indicate renal and 
pancreatic dysfunction deterioration compared to non-
treated CLI animals. Serum triglycerides tended up (by 
17%, p>0.1) and ALP – declined (by 50%) (Fig. 5).
Under C60FAS p.o. action, hepatic dystrophy was lesser 
compared to non-treated CLI animals, lymphocytic 
infiltration and fibrosis of portal tracts also were 
diminished. However, blood vessels and hemocapillars 
remained dilated and overflowed, thrombosis features 
and necrotic foci still occurred (Fig. 4, Table 3). ALT 
and conjugated bilirubin restored to control values, 
but unconjugated bilirubin even more increased (up 
to 6 times compared to control). Creatinine and urea 
were maintained at the level of APAP group. Serum 
α-amylase and triglycerides also increased (by 35% and 
87%, respectively) in these animals like under C60FAS i.p. 
application (Fig. 5). 
Serum triglycerides elevation might indicate liver 
dysfunction, in particular, the glutathione system 
disorders, such as inhibition of glutathione synthesis and/
or modification of metabolic pathways responsible for 
xenobiotics detoxifying.52 Recently, we have shown that 
C60 caused depletion of reduced glutathione pool in liver 
probably through upregulation of glutathione peroxidase 
which uses reduced glutathione as a substrate.32
EGFR expression 
C60FAS inhibited the expression of EGFR in HepG2 cells 
after 48 hours incubation in a dose-dependent manner 
(Fig. 6): there were 41±2% immunopositive cells in control 
and only 25.3±1.3% and 12.3±0.6% in C60FAS 10 μg/mL 
and C60FAS 100 μg/mL groups, respectively.
Discussion
APAP is one of the most widely used analgesic and antipyretic 
medications. It is safe and effective if used at recommended 
doses, while overdose can lead to hepatotoxicity and ALF. 
APAP-induced hepatotoxicity is the most common cause 
of ALF. APAP is metabolized in liver, predominantly via 
UDP-glucuronosyltransferase and sulfotransferase, to 
non-toxic urine-excreted compounds. However, 5-9% of 
APAP is metabolized by cytochromes P450, preferably 
CYP 2E1, to the highly reactive metabolite N-acetyl-p-
benzoquinone imine (NAPQI). Usually, NAPQI rapidly 
conjugates with glutathione, but APAP overdose depletes 
hepatic glutathione pool, an excessive amount of NAPQI 
covalently binds to sulfhydryl groups of cellular proteins, 
in particular mitochondrial ones, which ultimately 
result in mitochondrial dysfunction and oxidative 
stress, and lead to hepatocytes necrosis.53,54 Generally, 
biotransformation of certain xenobiotics by the enzymes 
of CYP family is accompanied by the production of short-
lived highly reactive metabolites, such as electrophiles, 
nucleophiles, free radicals, and redox-active reactants. 
These chemical species can covalently bind cellular 
proteins and lipids, and in case of overproduction cause 
damage of cellular organelles, including mitochondria, 
and lead to development of oxidative stress, endoplasmic 
reticulum stress, hepatocytes apoptosis and necrosis.55 
These events have been suggested the background of liver 
toxic injury.
The assessment of antioxidants effect under toxic liver 
injury, in particular DILI, viral and non-viral hepatitis, 
alcoholic liver disease and NASH were aimed to be 
discovered in numerous in vitro and in vivo studies. The 
therapeutic efficacy of vitamins C and E, silymarin, 
N-acetylcysteine, glycyrrhizinic and ursodeoxycholic 
acids, plant extracts and antioxidant mixtures were 
Table 3. Pathological changes of liver of CLI rats receiving C60FAS
Pathological changes
Experimental groups
Control APAP APAP+C60FAS i.p. APAP+C60FAS p.o.
Protein dystrophy of hepatocytes - +++ ++ +
Lipid dystrophy of hepatocytes - +++ ++ -
Ground-glass hepatocytes - +++ + +
Necrotic hepatocytes - +++ + ++
Apoptotic hepatocytes - +++ + +
Connective tissue accumulation - +++ + ++
Lymphocytes accumulation + +++ + ++
Blood vessel dilation - +++ + ++
Note. APAP: acetaminophen, C60FAS: C60 fullerene aqueous colloid solution, i.p.: intraperitoneally, p.o.: per os.; trait intensity: “-“ – not observed, “+”: single or slight, “++”: 
moderate, “+++”: strong.
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demonstrated in combination therapy and separately.6,56 
Nevertheless, their clinical effectiveness still remains 
unproved. The only drug approved in clinical practice 
for DILI treatment is N-acetylcysteine - APAP specific 
antidote. However, this remedy is less effective in case of 
non-APAP ALF.14 In the setting of DILI with autoimmune 
features and hypersensitivity reactions, corticosteroids 
have been used predominantly.57 It should be noticed 
that all the abovementioned non-hormonal agents 
possess antioxidant properties which contribute to their 
therapeutic activity.10,11,14,58-60 These chemicals can affect 
the signaling pathways associated with the production 
and/or neutralization of free radicals and proinflammatory 
cytokines and, moreover, can directly scavenge free 
radicals.61,62 Pristine C60 is one of the most powerful free 
radical scavengers.33,63,64 One C60 molecule is able to bind 
up to 34 radicals depending on their size.65 Therefore, we 
suggest that therapeutic effects of C60 might be realized 
through its strong antioxidant properties. Indeed, the 
ability of C60 to inhibit lipid peroxidation and to stimulate 
antioxidant defense enzymes under CCl4-induced ALI 
were shown.30 We also proved this ability of C60 on model 
Fig. 5. Serum biochemical markers of liver, pancreas and kidney functional states for CLI rats received C60FAS normalized against control: 1 – control; 
2 – APAP; 3 – APAP+C60FAS i.p.; 4 – APAP+C60FAS p.o.; *P<0.05 compared to control, 
#P<0.05 compared to APAP.
Fig. 6. EGFR expression in HepG2 cells after 48 h incubation with C60FAS: 1 – control; 2 – C60FAS 10 µg/mL; 3 – C60FAS 100 µg/mL. Antibodies V9 clon 
(IS630, Dako, USA) and hematoxylin staining, ×400, scale 100 µm
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What is the current knowledge?
√ Toxic liver injury is accompanied by oxidative stress and 
has no universal and effective treatment.
What is new here?
√ Water-soluble pristine C60 fullerenes as the powerful 
free radical scavengers reduce the local and systemic 
manifestations of toxic liver injury in rats.
√ C60 fullerenes inhibit EGFR expression in HepG2 cells.
Research Highlightsof colonic inflammation.
32 
We have shown that C60 could suppress EGFR 
expression in HepG2 cells. EGFR is known to be involved 
in liver regeneration. Its upregulation is tightly related to 
liver fibrogenesis and fibrosis and cirrhosis development, 
and its downregulation attenuates the fibrotic lesions.66 
Therefore, mitigation of periportal fibrosis under C60FAS 
chronic exposure might be through inhibition of EGFR 
expression by that. Additionally, the rapid downregulation 
of EGFR under acute APAP-induced liver injury diminishes 
liver damage and inhibits cell necrosis possibly by another 
mechanism. Hence, it was shown67 that immediately after 
APAP application (within 1-4 h) EGFR is overexpressed 
and upregulated and translocated in mitochondria, and 
the intensity of these events correlates with the rate of 
liver necrotic lesions. Moreover, the administration of 
EGFR inhibitor in this period reduces and even eliminates 
completely APAP toxic effects on liver. Authors explained 
this phenomenon by the fact that EGFR activation is 
involved in apoptosis through its ability to phosphorylate 
“death receptor” (CD95) and stabilize the death-inducing 
signaling complex. Accordingly, inhibition of EGFR 
results in inhibition of apoptosis. Therefore, we might 
suggest that inhibition of EGFR could contribute to 
hepatoprotective effect of C60.
Some studies revealed that C60 could realize prooxidative 
effects in biological systems and cause oxidative DNA 
damage.41 However, these effects strongly depend on C60 
nanoparticles size and dozing. The C60 system we have 
used in the current study did not demonstrate any toxic or 
another effects which could be interpreted as prooxidative 
ones.29,32,34,37,40 Nevertheless, possible accumulation of C60 
in tissues and organs especially after prolonged exposure68 
should not be neglected. Therefore, local high amount of 
C60 in some organs, for instance in pancreas, might occur. 
The last could cause observed negative effects like renal 
and pancreatic hypofunction.
Conclusion
We concluded that C60FAS application reduces the 
hepatocytes cytolysis and restores the liver morphological 
state, but affects the bilirubin metabolism through APAP-
induced ALI. C60FAS also contributes to the recovery of 
renal and pancreatic functions. 
Under chronic APAP exposure, C60FAS attenuates the 
dystrophic processes in hepatocytes and manifestations of 
apoptosis and necrosis, as well as normalizing the values of 
most liver functional biochemical markers. However, renal 
and pancreatic dysfunction features also occur, suggesting 
the possible cumulative effects of C60. Therapeutic effects 
of C60 might be realized through its ability to scavenge free 
radicals and affect the expression of EGFR.
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